Cargando…
The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
Trials on cardiovascular and renal outcomes in patients with type 2 diabetes have consistently demonstrated that sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of diabetic kidney disease (DKD) progression. However, their renal protective mechanisms have yet to be completely unders...
Autores principales: | Li, Zi, Murakoshi, Maki, Ichikawa, Saki, Koshida, Takeo, Adachi, Eri, Suzuki, Chigure, Ueda, Seiji, Gohda, Tomohito, Suzuki, Yusuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714078/ https://www.ncbi.nlm.nih.gov/pubmed/33098615 http://dx.doi.org/10.1002/2211-5463.13014 |
Ejemplares similares
-
Aspartic acid supplementation ameliorates symptoms of diabetic kidney disease in mice
por: Ichikawa, Saki, et al.
Publicado: (2020) -
Circulating kidney injury molecule‐1 as a biomarker of renal parameters in diabetic kidney disease
por: Gohda, Tomohito, et al.
Publicado: (2019) -
Progranulin and Its Receptor Predict Kidney Function Decline in Patients With Type 2 Diabetes
por: Murakoshi, Maki, et al.
Publicado: (2022) -
Fractional excretion of tumor necrosis factor receptor 1 and 2 in patients with type 2 diabetes and normal renal function
por: Gohda, Tomohito, et al.
Publicado: (2020) -
Differential organ-specific inflammatory response to progranulin in high-fat diet-fed mice
por: Murakoshi, Maki, et al.
Publicado: (2021)